• Publications
  • Influence
In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum.
The in vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline was compared against chloroquine-resistant and -susceptible strains of Plasmodium falciparum using a semi-microExpand
  • 60
  • 3
Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing
ABSTRACT In a dose-ranging study of amprenavir (formerly 141W94), an inhibitor of the protease enzyme of human immunodeficiency virus (HIV) type 1, single-dose and steady-state pharmacokineticExpand
  • 90
  • 3
Abacavir: Absolute Bioavailability, Bioequivalence of Three Oral Formulations, and Effect of Food
Study Objectives. Study A: to determine the absolute bioavailability of a single 300‐mg abacavir hemisulfate tablet. Study B: to determine the bioequivalence of two oral abacavir formulations (300‐mgExpand
  • 52
  • 3
In Vivo Effect of α1-Acid Glycoprotein on Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Protease Inhibitor
ABSTRACT Observations from early clinical pharmacology studies of amprenavir, an inhibitor of human immunodeficiency virus type 1 (HIV-1) protease that is highly bound to human plasma proteinsExpand
  • 35
  • 3
The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
AIMS Zolmitriptan (311C90), a novel, selective, centrally and peripherally acting 5-HT1D-receptor agonist is under development as an acute treatment for migraine. The tolerability, pharmacokineticsExpand
  • 41
  • 3
  • PDF
A Comparison of the Steady‐State Pharmacokinetics and Safety of Abacavir, Lamivudine, and Zidovudine Taken as a Triple Combination Tablet and as Abacavir plus a Lamivudine‐Zidovudine Double
Study Objective. To investigate the steady‐state pharmacokinetics of a triple combination tablet containing abacavir (ABC) 300 mg, lamivudine (3TC) 150 mg, and zidovudine (ZDV) 300 mg takenExpand
  • 40
  • 2
Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function
ABSTRACT Amprenavir (141W94) is extensively metabolized by P450 cytochromes, specifically, CYP3A4. Because hepatic insufficiency reduces P450-mediated metabolism, the concentrations in plasma ofExpand
  • 76
  • 1
  • PDF
Type RI resistance to halofantrine in West Africa.
A case of recrudescent falciparum malaria after halofantrine treatment is described. The patient contracted Plasmodium falciparum in Ivory Coast and was treated with halofantrine. Plasma levels ofExpand
  • 22
  • 1
Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients
The plasma concentrations of the enantiomers of halofantrine and its N-desbutyl metabolite in six patients with malaria were measured after oral administration of 3×750 mg doses of micronised,Expand
  • 23
  • 1
Pharmacokinetic Interaction between Amprenavir and Clarithromycin in Healthy Male Volunteers
ABSTRACT The P450 enzyme, CYP3A4, extensively metabolizes both amprenavir and clarithromycin. To determine if an interaction exists when these two drugs are coadministered, the pharmacokinetics ofExpand
  • 35
  • 1
  • PDF